CClinicalTrials.gg
RecruitingNCT07020611ASCENDUpdated Dec 9, 2025

First-In-Human Study Evaluating Aneurysm Sac Lining in AAA Patients

An interventional study of Cygnum Aneurysm Sac Management Device (ASMD) in Abdominal Aortic Aneurysm, sponsored by Life Seal Vascular Inc.. Recruiting at 1 site in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Life Seal Vascular Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety and feasibility of the Cygnum Aneurysm Sac Management Device in patients with abdominal aortic aneurysms treated with endovascular aneurysm repair (EVAR). The main questions it aims to answer are:

  1. Is the Cygnum device safe when used adjunctively with standard EVAR endografts?
  2. Does it effectively reduce or prevent type II endoleaks by managing the aneurysm sac?

Participants will:

  1. Undergo EVAR with adjunctive implantation of the Cygnum device
  2. Have follow-up imaging (e.g., CT scans) and clinical assessments to evaluate device position and sac behavior over time
02

Conditions studied

  • Abdominal Aortic Aneurysm
03

In context

Aortic Aneurysm, Abdominal

473 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 100 are open to participants now.

This study's planned enrollment of 15 is below the median of 66 across 233 interventional studies indexed under Aortic Aneurysm, Abdominal.

Browse Aortic Aneurysm, Abdominal studies →

Lead sponsor

This is the only study on the registry with Life Seal Vascular Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent
  • Patient is willing to complete the follow-up according to the requirements of the protocol.
  • Patient AAA anatomy complies with "instructions for use" for commercial EVAR devices used
  • ≥18 years old
  • Abdominal aortic aneurysm with sac diameter ≥ 5.5cm in males and ≥ 5.0cm in females
  • Maximum blood flow luminal diameter ≤ 50mm
  • Eligible for endovascular aneurysm repair based on anatomical considerations, such as adequate iliac/femoral access
  • Patient is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Concomitant Common Iliac Artery aneurysms ≥ 25mm
  • Life expectancy \<2 years
  • Already participating in an investigational drug or device study
  • Known allergy or contraindication to any study device material
  • Coagulopathy or uncontrolled bleeding disorder
  • Ruptured, leaking, inflammatory or mycotic aneurysm
  • Connective tissue diseases (e.g., Marfan Syndrome)
  • Unsuitable vascular anatomy that may interfere with device introduction or deployment, in the opinion of the investigator
  • Aneurysmal or dissected disease of the descending thoracic aorta
  • Previous surgical or EVAR repair for AAA
  • Myocardial infarction and/or major heart surgery ≤ 90 days prior to the procedure
  • Transient Ischemic Attack or stroke ≤ 90 days prior to the procedure
  • Unstable angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia or valvular disease ≤ 30 days prior to the procedure
  • Unable or unwilling to comply with study follow-up requirements
  • Serum creatinine level ≥ 180 µmol/L
  • Patients of childbearing potential who are pregnant or planning to become pregnant during the course of the study
  • Patient has other medical, social or psychological problems that, in the opinion of the investigator, study involvement would not be in their best interest.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Cygnum ASMD Arm

    Device: Cygnum Aneurysm Sac Management Device (ASMD)

Interventions

  • DeviceCygnum Aneurysm Sac Management Device (ASMD)

    Cygnum ASMD, adjunctive to EVAR, lines the aneurysmal wall to prevent type II endoleaks

06

What researchers measure

Primary outcomes

  1. Incidence of major adverse events (MAEs)

    Rate of related major adverse events (MAEs)

    Time frame: 30 days post-procedure

  2. Procedural Technical Success

    Technical success, defined as lining the AAA sac wall with the investigational devices

    Time frame: Immediately after the intervention

Secondary outcomes

  1. Incidence of related major adverse events (MAEs)

    Incidence rate of related major adverse events (MAEs)

    Time frame: 12 months post procedure

  2. Incidence of related serious adverse events (SAEs)

    Incidence rate of related serious adverse events (SAEs)

    Time frame: 12 months post procedure

  3. Efficacy - Type II endoleaks

    Incidence of type II endoleaks

    Time frame: 12 months post procedure

  4. Efficacy - AAA sac diameter

    Change in AAA sac diameter

    Time frame: 12 months post procedure

07

Study locations

1 of 1 sites recruiting
  • Auckland City Hospital
    Auckland, New Zealand
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07020611
Lead sponsor
Life Seal Vascular Inc.
Collaborators
Auckland City Hospital
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Nov 26, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2028 (estimated)
Last update
Dec 9, 2025

Study contacts

Raja N Ghanem
Contact
contact@lifesealvascular.com
612-840-2723
Raja Ghanem
study director · Life Seal Vascular Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion